CombiMatrix Corporation announces that its wholly owned subsidiary, Combimatrix Molecular Diagnostics (CMDX), has entered into a new partnership with Lenetix, a New York based laboratory, to co-market CMDX’s suite of array CGH based tests including its BAC HD Scan™ test, a comprehensive test for characterizing genomic causes of childhood developmental disorders.
The BAC HD Scan test can identify over 290 genomic causes of developmental disorders and is routinely used in postnatal genetic diagnostics. Also included in CMDX’s suite of developmental genomic tests is the Prenatal Scan array CGH test, a more customized test specifically designed and validated for use in prenatal genetic diagnostics.
Both companies will launch their co-marketing endeavors at the upcoming Society of Maternal-Fetal Medicine 29th Annual Meeting in San Diego (Jan 26-30th, 2009).
“By accurately determining the genomic cause, or etiology, of an unprecedented number of childhood development disorders, and facilitating such diagnosis in as timely a manner as possible, the BAC HD Scan test removes the anxiety associated with undiagnosed cases of developmental delay, provides critical genomic information for the appropriate genetic counseling of parents and provides parents and caregivers the most data-driven expectation of clinical developmental outcome of their child. Our collaboration with Lenetix will help us increase awareness of our tests among primary care physicians including pediatricians, genetic counselors and obstetricians-gynecologists — key customers of Lenetix,” said Dr Mansoor Mohammed, President and Chief Executive Officer of Combimatrix Molecular Diagnostics.
“Lenetix prides itself on offering our clients and patients the most appropriate and rigorously validated tests in the pre- and postnatal genetic testing genre. CMDX’s portfolio of array CGH tests have become routine requisitions in the genetic diagnostic community and exceed our exacting standards,” said Leonard Kellner, Lenetix’s President and CEO.
Source: Globe Newswire